Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
165
resultados
Última actualización
28/09/2025 [07:28:00]
Resultados 25 a 50 de 165
Resumen de: WO2025194036A1
The present disclosure is generally directed to tetracyclic analogs that modulate autophagy in a subject suffering from alpha-1 antitrypsin deficiency (ATD) and possibly other autophagy associated diseases or disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.
Resumen de: WO2025193848A1
Provided are compositions for delivery of zinc finger fusion proteins that inhibit expression of tau in the nervous system using the blood-brain barrier penetrant AAV capsid proteins comprising SEQ ID. NO: 1235, and methods of using the compositions to treat neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, and other tauopathies.
Resumen de: WO2025192800A1
The present invention relates to a pharmaceutical composition for preventing or treating Alzheimer's disease, the composition comprising, as an active ingredient, neural crest-derived nasal turbinate stem cells (NTSCs) expressing SSEA3 and CD105. Treatment with the NTSCs expressing SSEA3 and CD105 or with an NTSC cell line including at least a predetermined proportion of the NTSCs was found to result in remarkably good therapeutic activity against Alzheimer's disease. Therefore, the present invention is expected to be effectively used not only as a composition for preventing or treating Alzheimer's disease in which the composition includes, as an active ingredient, NTSCs expressing SSEA3 and CD105 or an NTSC cell line including at least a predetermined proportion of the NTSCs, but also for uses such as screening of NTSC formulations that can be used to treat Alzheimer's disease, or prediction of the therapeutic efficacy thereof.
Resumen de: EP4616852A2
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanaminehydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
Resumen de: EP4617286A2
The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fe-mediated crosslinking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
Resumen de: WO2025185724A1
Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Resumen de: WO2025188734A1
The present disclosure provides methods of treating Alzheimer's disease and other disorders using (4R,5R)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one (Compound 1).
Resumen de: WO2025188619A1
Described herein, in part, are methods useful for preventing and/or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as Parkinson's disease, psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.
Resumen de: WO2025186220A1
The present invention relates to peptides for treatment of cognitive diseases, in particular Alzeheimer's Disease, mild cognitive impairment due to Alzheimer's disease, and mild dementia due to Alzheimer's disease.
Resumen de: WO2025186332A1
The present invention is in the field of AAV vectorized TDP-43 specific antibodies and uses thereof. The present invention further relates to means and methods to prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43, or TDP-43 proteinopathy, including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: AU2024222862A1
The invention provides berberine tauroursodeoxycholate (BTUDC), pharmaceutical compositions and methods of use thereof for the treatment, reduction and/or prevention of Parkinson's disease, or an associated disease and disorder, as monotherapy or in combination with other agents or as an adjuvant. The invention further provides pharmaceutical compositions and methods of use of berberine (BBR) and tauroursodeoxycholic acid (TUDCA) for the treatment, reduction and/or prevention of Parkinson's disease, or an associated disease and disorder, as monotherapy or in combination with other agents or as an adjuvant.
Resumen de: US2025283074A1
Provided are methods for treating Alzheimer's Disease and/or ameliorating at least one symptom thereof. In some embodiments, the methods include administering to a. subject with AD an inhibitor of a clusterin biological activity, wherein the composition is administered via a route and in an amount sufficient to inhibit the clusterin biological activity to thereby treat the subject's. AD and/or ameliorate at least one symptom thereof. Also provided are methods for reducing and/or inhibiting myelin decay in a subject in need thereof and methods for inhibiting differentiation of oligodendrocyte progenitor cells (OPCs) to mature oligodendrocytes, the method comprising contacting the OPCs with a clusterin gene product or a functional fragment or derivative thereof.
Resumen de: US2025282724A1
The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1):wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.
Resumen de: US2025282725A1
Small molecule potentiatiors to potassium channels (such as Kv7 potentiators—which are also called KCNQ potentiators), compositions including such compounds, and methods of using such compounds for the treatment of Amyotrophic Lateral Sclerosis and other neurological diseases caused by changes in motor neuron excitability, including, but not limited to, primary lateral sclerosis, pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy and epilepsy.
Resumen de: US2025282838A1
The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide.
Resumen de: US2025283075A1
The present disclosure provides methods for treating inflammatory disease, such as Alzheimer's disease, by administering an inhibitor of Fli-1, such as an antisense oligonucleotide. Further provided are antisense gapmer oligonucleotides for targeting Fli-1.
Resumen de: US2025281500A1
Compositions and methods for treating Huntington's disease with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with pridopidine, or a pharmaceutical salt thereof, are provided. The compositions and methods may be used to improve one or more symptoms of Huntington's disease.Formula (I):or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.
Resumen de: US2025281488A1
The present invention relates to inhibitors of Valosin-containing protein (VCP or p97) and the use thereof in the treatment or prevention of diseases such as amyotrophic lateral sclerosis (ALS). In particular the present invention provides VCP inhibitors for use in a method of treating or preventing ALS wherein the subject has been identified as not having a disease-causing genetic mutation in a VCP gene (non-VCP-associated ALS). The invention also relates to methods of identifying a patient as not having a disease-causing mutation in a VCP gene.
Resumen de: US2025281466A1
New treatments using Clopidogrel, Ticagrelor, Prasugrel, and/or Cangrelor and new uses for Clopidogrel are disclosed herein. For example, it has been found that conditions such as ALS (Amyotrophic Lateral Sclerosis), Alzheimer's Disease, the normal aging process, nerve damages, nerve injuries, muscular dystrophy, strenuous physical activities, fatigue, and other conditions that affect synapses as well as skeletal muscles can be treated using Clopidogrel or pharmaceutically acceptable other forms. New mechanisms and modes of action are explained herein.
Resumen de: US2025281430A1
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in human patients for treating neurological and psychiatric conditions, such as agitation associated Alzheimer's disease and/or reducing relapse of agitation in Alzheimer's disease.
Resumen de: US2025282852A1
Provided herein are methods of promoting removal of beta-amyloid (Aβ) plaque, methods of reducing neuroinflammation, and methods treating a neurological disorder (e.g., Alzheimer's Disease) with certain bispecific antibodies or antigen-binding fragments with one specificity against an internalizing antigen expressed on the surface of neurological cells and the other specificity against a toxic form of Aβ protein. Exemplary antibodies, characteristics thereof, and methods of screening for additional therapeutic bispecific antibodies are also described herein.
Resumen de: EP4613278A1
The present invention relates to a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease, comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The present invention provides a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease (AD), comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The strain of the present invention has the excellent effects of reducing amyloid beta protein (Aβ) or tau protein (Tau) and improving cognitive function, and thus can be effectively used as a composition for preventing, alleviating or treating cognitive impairment or AD.
Resumen de: EP4613277A1
The present invention relates to a composition for preventing, ameliorating or treating cognitive dysfunction or Alzheimer's disease comprising, as an active ingredient, Lactobacillus fermentum SRK414 strain which has accession number KCTC13687BP. The strain of the present invention is excellent in reducing barrier permeability and reducing amyloid beta and tau proteins and has an excellent effect in improving cognitive function, and accordingly, the strain can be useful for a food and therapeutic agent for same purposes.
Resumen de: WO2024097164A1
Provided are methods of phosho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Nº publicación: EP4613281A1 10/09/2025
Solicitante:
KOREA INST ORIENTAL MEDICINE [KR]
GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR [KR]
Korea Institute of Oriental Medicine,
Gyeonggido Business & Science Accelerator
Resumen de: EP4613281A1
The present invention relates to a composition for preventing, ameliorating, or treating Alzheimer's disease comprising grapevine stem extract or a compound isolated therefrom as an effective component. Specifically, as the grapevine stem extract and vitisin A as an effective component of the present invention exhibit an excellent effect of inhibiting infection with the herpes simplex virus and inhibiting Alzheimer-causing factors in the brain tissue of animal models infected with the herpes simplex virus, the composition of the present invention can be advantageously used as an agent for treating Alzheimer's disease or a functional health food or an animal feed additive for preventing or ameliorating Alzheimer's disease.
BOPI
Sede Electrónica
